ESR1 and cancer: Effectiveness of combining endocrine therapy with mTOR inhibitors has been tested in several trials, including the TAMRAD trial, a randomized phase 2 trial of tamoxifen with or without everolimus in postmenopausal women with AI-resistant, ER+, advanced cancer.